Table 2. Patients baseline characteristics.

	GnRH agonists	GnRH antagonists	p-value
Age (years)	30.7±3.88	30.5±3.03	0.88
BMI (kg/m2)	23.1±2.68	22.7±2.80	0.72
Oestradiol level on day of hCG (nmol/L)	5.3±2.3	4.6±2.4	0.48
Retrieved oocytes (n)	11.7±5.24	8.0±3.89	0.08
Degenerated (ratio)	0.02±0.05	0.04±0.11	0.46
MI (proportion)	0.07±0.08	0.14±0.15	0.19
MII (proportion)	0.91±0.08	0.82±0.21	0.18
Fertilized (proportion)	0.65±0.14	0.50±0.19	0.06
MII-NF (proportion)	0.68±0.08	0.62±0.22	0.36
MII-BL (proportion)	0.23±0.08	0.20±0.07	0.31
Endometrial lining thickness (mm)	9.91±1.58	9.8±0.63	0.84
Pregnancy rate per cycle (proportion)	0.55±0.16	0.60±0.16	0.81
Delivery rate per cycle (proportion)	0.55±0.16	0.40±0.16	0.53
Frozen embryos remained (number)	0.70±0.95	0.40±0.70	0.43

age, body mass index (BMI), serum oestradiol level on day of hCG, number of retrieved oocytes; proportions of degenerated oocytes, metaphase I oocytes (MI), metaphase II oocytes (MII), fertilized oocytes, unfertilized metaphase II oocytes (MII-NF) and metaphase II oocytes developed to the blastocyst stage (MII-BL). Significance of differences between the two treatment groups was assessed using Student's t-test; two-tailed p-values are shown.